Leerink Partners Cuts Price Target on DexCom (DXCM) Following 3Q

DexCom (DXCM): Cutting PT On Temporary Market Weakness - Wedbush

Wedbush analyst, Tao Levy, reiterated his Outperform rating on shares of DexCom (NASDAQ: DXCM) but cut the price target to $100 from $112 due to near-term uncertainty that Medtronics product launches have created on near-term purchasing patterns of diabetes technology. However, the analyst remains optimistic... More

After-Hours Stock Movers 11/01: (PTN) (AVXS) (EA) Higher; (ADPT) (ZAGG) (DXCM) Lower (more...)

Today's After-Hours Movers

Adeptus Health (NYSE: ADPT) 48% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.

Palatin Technologies, Inc. (NYSE: PTN) 46.9% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met the... More

DexCom (DXCM) Misses Q3 EPS by 9c

DexCom (NASDAQ: DXCM) reported Q3 EPS of ($0.22), $0.09 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $148.6 million versus the consensus estimate of $146.26 million.

For earnings history and earnings-related data on DexCom (DXCM) click here.

Trading Radar for 11/1: Kellogg (K), Electronic Arts (EA), Mosaic (MOS), Herbalife (HLF), Western Union (WU) Report

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Adeptus Health (NYSE: ADPT) - consensus EPS $0.56
Aircastle Limited (NYSE: AYR) - consensus EPS $0.43
Allot Communications (Nasdaq: ALLT) - consensus EPS $0.02
Ameresco (NYSE: AMRC) - consensus EPS $0.09
Ametek (NYSE: AME) - consensus EPS $0.55
Ampco-Pittsburgh (NYSE: AP) - no Street consensus... More

BTIG Upgrades DexCom (DXCM) to Buy

BTIG upgraded DexCom (NASDAQ: DXCM) from Neutral to Buy with a price target of $92. Analyst Sean Lavin sees an attractive entry.

"When the stock had hit the mid $90s we felt risk reward was balanced with upside to be driven by... More